Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared on LinkedIn:
‘‘NovoNordisk has applied to the FDA for approval of Mim8, a bispecific antibody which will be a direct competitor to emicizumab (Hemlibra).
The data we have seen presented at scientific meetings and published are strong, and suggest that approval is likely to be given.”
Read the full article here.
Article: Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
Stay updated on the emerging in the field of Hemophilia with Hemostasis Today.
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage
-
Feb 23, 2026, 11:29Emma Lefrancais: Uncovering A Key Role for The IL-33/ST2 Axis in Platelet Biology with Lucie Gelon
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities